Clinical Trial

InsightRX to Present Abstracts On Vancomycin Pharmacokinetic Model Performance, MIPD Protocols at ACoP15 Conference

SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- InsightRX – the leader in Bayesian model-informed precision dosing (MIPD) software – today announced it…

2 months ago

PIECES TECHNOLOGIES AWARDED $2M FROM NATIONAL CANCER INSTITUTE, PART OF THE NATIONAL INSTITUTES OF HEALTH, TO ADVANCE USE OF CONVERSATIONAL AI TO IMPROVE THE CARE OF CANCER PATIENTS

Pieces will deploy new conversational AI at MetroHealth that will interact directly with cancer patients and leverage pioneering human oversight…

2 months ago

Cellev8 and Zyppah Team Up to Give Snoring a Rest

Cellev8 and Zyppah Announce Collaborative Sales Agreement Targeting 90 Million Snoring Americans.WELLINGTON, FL / ACCESSWIRE / October 29, 2024 /…

2 months ago

Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

SEATTLE WA AND LUND, SWEDEN / ACCESSWIRE / October 29, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB…

2 months ago

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today…

2 months ago

Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio

FREIBURG, GERMANY / ACCESSWIRE / October 29, 2024 / Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos…

2 months ago

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia

TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical…

2 months ago

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15,…

2 months ago

Immutep Quarterly Activities Report Q1 FY25

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding…

2 months ago